[Prodrugs].
Järvinen
T
T
Kuopion yliopiston farmaseuttisen kemian laitos.
Rautio
J
J
Niemi
R
R
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics; D000998:Antiviral Agents / Q000493:pharmacokinetics; D004837:Epinephrine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005387:Finland; D006801:Humans; D010406:Penicillins / Q000493:pharmacokinetics; D011355:Prodrugs / Q000009:adverse effects / Q000493:pharmacokinetics*; D013678:Technology, Pharmaceutical; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D000806:Angiotensin-Converting Enzyme Inhibitors; D000998:Antiviral Agents; D010406:Penicillins; D011355:Prodrugs; D004917:Erythromycin; C015173:dipivefrin; C056625:erythromycin 2'-acetate; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir; D004837:Epinephrine